Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06710548 · ClinicalTrials.gov registry record · NA
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
A NA study of Ovarian Cancer and Primary Peritoneal Cancer, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 240
- Enrollment target
- 6
- Study locations
NCT06710548: Recruiting NA study of Ovarian Cancer and Primary Peritoneal Cancer, sponsored by Dana-Farber Cancer Institute.
NCT06710548 is a NA study of Ovarian Cancer and Primary Peritoneal Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 240 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (67% lower). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06710548, a NA study of Ovarian Cancer and Primary Peritoneal Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to see whether a supportive intervention (REVITALIZE) reduces fatigue and its impact on daily life and activities for participants with ovarian cancer taking PARP inhibitors. The name of the study groups in this research study are: 1. REVITALIZE 2. Educational Materials
Primary Outcome
Assessed by the 7-item Fatigue Interference subscale of the Fatigue Symptom Inventory (FSI). Items are rated on an 11-point scale (0 = no interference; 10 = extreme interference), with a total scores range of 0 to 70 with the higher score representing greater fatigue interference with daily life. The mean change from baseline to the follow up time point (20 weeks) will be computed using a two-sample t-test with a 0.95 confidence interval.
Conditions Studied
Interventions
- BEHAVIORAL REVITALIZE Intervention
- BEHAVIORAL Educational Materials
Study Locations (6)
Massachusetts
- Massachusetts General Hospital-Cancer Center - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Colorado
- University of Colorado Cancer Center-Anschutz - Aurora
- University of Colorado Boulder - Boulder
North Carolina
- Duke Cancer Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-03-17 |
| Est. Completion | 2029-01-31 |
| Phase | NA |
What NCT06710548 shows while recruiting
NCT06710548 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (67% lower).
The record links to 7 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which REVITALIZE Intervention is the first listed.
NCT06710548 lists 6 locations in 3 states (Massachusetts, Colorado, North Carolina).
Frequently Asked Questions
What is clinical trial NCT06710548 about?
NCT06710548 is a clinical study titled "REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors". The purpose of this study is to see whether a supportive intervention (REVITALIZE) reduces fatigue and its impact on daily life and activities for participants with ovarian cancer taking PARP inhibitors. The name of the study groups in this research study are: 1. REVITALIZE 2. Educational Material...
What is the current status of trial NCT06710548?
This trial is currently recruiting. It is a NA study. The enrollment target is 240 participants. The study started on 2025-03-17. Estimated completion is 2029-01-31.
What conditions does trial NCT06710548 study?
This clinical trial studies the following conditions: Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, PARP Inhibitor.
What interventions are being tested in trial NCT06710548?
The interventions under investigation include: REVITALIZE Intervention (BEHAVIORAL), Educational Materials (BEHAVIORAL).
Who is sponsoring clinical trial NCT06710548?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06710548 being conducted?
This trial has 6 study locations across Colorado, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06710548's enrollment target sits among peer trials
240 83rd of 322 higher than 239 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
RECRUITING · NA
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
RECRUITING · NA
-
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
RECRUITING · NA
-
Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI